The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis

Journal of Dermatological Treatment

Volumn 17, Issue 6, 2006, Pages 362-369

  Langewouters, Annechien M G ^a,b   Van Erp, Piet E J ^a   De Jong, Elke M G J ^a   Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alefacept; Efficacy; NK receptors; Psoriasis; Safety; T cell subsets

Indexed keywords

ALEFACEPT; ANTIBIOTIC AGENT; CD161 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CD94 ANTIGEN; CYCLOSPORIN A; ETRETIN; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INJECTION SITE REACTION; MALE; MEDICAL ASSESSMENT; OPPORTUNISTIC INFECTION; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; SCORING SYSTEM; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ACITRETIN; ADULT; AGED; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 34250207338     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601028794     Document Type: Article

References (16)

1. Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B, et al. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Ther Immunol. 1994;1:205-16.
2. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-55.
3. Kraan MC, van Kuijk AWR, Dinant HJ, Goedkoop AY, Smeets TJM, de Rie MA, et al. Alefacept treatment in psoriatic arthritis - Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002;46:2776-84.
4. Krueger GG, Lebwohl M, Griffiths CEM, Dinant HJ, Goedkoop AY. Alefacept (LFA-3/IgG(1)) selectively targets CD45RO(+) T cells, producing durable improvements in psoriasis and psoriatic arthritis. Allergy. 2002;57:61-2.
5. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plague psoriasis. J Am Acad Dermatol. 2002;47:821-33.
6. Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg. 2004;8:14-19.
7. Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol. 2003;42:224-30.
8. Ortonne JP. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17:12-16.
9. Korman NJ, Moul DK. Alefacept for the treatment of psoriasis: A review of the current literature and practical suggestions for everyday clinical use. Semin Cutan Med Surg. 2005;24:10-18.
10. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CEM. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-27.
11. Ortonne JP, Khemis A, Koo JY, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2005;19:556-63.
12. Scheinfeld N. Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol Online J. 2005;11:7.
13. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin Cutan Med Surg. 2005;24:37-45.
14. Amevive (alefacept) Package Insert. Cambridge, MA: Biogen Inc., August 2004.
15. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol. 2003;148:784-8.
16. Krueger GG, van de Kerkhof PC. Safety of multiple courses of alefacept in combination with other psoriasis therapies: A study that reflects the clinical practice setting. J Am Acad Dermatol. 2004;50:P152 (Abstract P591).